Sorrento Therapeutics, Inc. (SRNE)
OTCMKTS
· Delayed Price · Currency is USD
0.0032
0.00 (0.00%)
Oct 16, 2024, 3:56 PM EDT
Sorrento Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 64.27 | 62.84 | 52.9 | 39.99 | 31.43 | 21.19 | Upgrade
|
| Revenue Growth (YoY) | 16.89% | 18.78% | 32.31% | 27.21% | 48.31% | -86.04% | Upgrade
|
| Cost of Revenue | 221.74 | 254.68 | 219.95 | 121.28 | 119.12 | 84.02 | Upgrade
|
| Gross Profit | -157.47 | -191.84 | -167.05 | -81.29 | -87.68 | -62.83 | Upgrade
|
| Selling, General & Admin | 193.54 | 182.34 | 196.86 | 116.18 | 103.56 | 63.64 | Upgrade
|
| Operating Expenses | 198.05 | 186.66 | 201 | 120.23 | 107.5 | 66.65 | Upgrade
|
| Operating Income | -355.52 | -378.5 | -368.05 | -201.53 | -195.18 | -129.48 | Upgrade
|
| Interest Expense | -6.81 | -8.57 | -10.22 | -20.16 | -35.05 | -57.63 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.92 | Upgrade
|
| Earnings From Equity Investments | -18.74 | -18.43 | -0.13 | -5.84 | -3.91 | -5.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.32 | - | - | - | -0.33 | -1.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.66 | 8.05 | -1.15 | 6.03 | -37 | 2.69 | Upgrade
|
| EBT Excluding Unusual Items | -382.41 | -397.45 | -379.54 | -221.49 | -271.46 | -189.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | -72.42 | -83.92 | -15.01 | - | - | - | Upgrade
|
| Asset Writedown | -45.78 | -124.19 | - | - | - | - | Upgrade
|
| Legal Settlements | -66.55 | -64.75 | - | - | - | - | Upgrade
|
| Other Unusual Items | -4.33 | 102.41 | -43.89 | -51.94 | -16.72 | -17.73 | Upgrade
|
| Pretax Income | -571.49 | -580.17 | -462.65 | -316.42 | -363.49 | -218.8 | Upgrade
|
| Income Tax Expense | 9.31 | -2.42 | -33.52 | -2.01 | -0.47 | -6.27 | Upgrade
|
| Earnings From Continuing Operations | -580.8 | -577.76 | -429.14 | -314.41 | -363.01 | -212.53 | Upgrade
|
| Minority Interest in Earnings | 32.81 | 4.91 | 0.81 | 15.95 | 70.94 | 8.99 | Upgrade
|
| Net Income | -548 | -572.84 | -428.33 | -298.46 | -292.07 | -203.54 | Upgrade
|
| Net Income to Common | -548 | -572.84 | -428.33 | -298.46 | -292.07 | -203.54 | Upgrade
|
| Shares Outstanding (Basic) | 508 | 419 | 295 | 230 | 133 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 508 | 419 | 295 | 230 | 141 | 106 | Upgrade
|
| Shares Change (YoY) | 50.62% | 42.25% | 28.26% | 63.56% | 32.37% | 50.82% | Upgrade
|
| EPS (Basic) | -1.08 | -1.37 | -1.45 | -1.30 | -2.20 | -1.92 | Upgrade
|
| EPS (Diluted) | -1.08 | -1.37 | -1.45 | -1.30 | -2.35 | -1.92 | Upgrade
|
| Free Cash Flow | -243.21 | -307.51 | -290.69 | -166.06 | -184.44 | -132.96 | Upgrade
|
| Free Cash Flow Per Share | -0.48 | -0.73 | -0.99 | -0.72 | -1.31 | -1.25 | Upgrade
|
| Gross Margin | -245.01% | - | - | -203.31% | -278.96% | -296.47% | Upgrade
|
| Operating Margin | -553.17% | -602.33% | -695.68% | -503.99% | -620.97% | -610.94% | Upgrade
|
| Profit Margin | -852.65% | -911.60% | -809.63% | -746.41% | -929.21% | -960.41% | Upgrade
|
| Free Cash Flow Margin | -378.42% | -489.37% | -549.47% | -415.31% | -586.78% | -627.39% | Upgrade
|
| EBITDA | -341.59 | -365.26 | -355.58 | -190.52 | -184.19 | -120.35 | Upgrade
|
| D&A For EBITDA | 13.93 | 13.25 | 12.46 | 11.01 | 10.99 | 9.12 | Upgrade
|
| EBIT | -355.52 | -378.5 | -368.05 | -201.53 | -195.18 | -129.48 | Upgrade
|
| Revenue as Reported | 64.27 | 62.84 | 52.9 | 39.99 | 31.43 | 21.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.